Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case series is unique in its focus on the intracran...

Полное описание

Библиографические подробности

Главные авторы:	Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2024-12-01
Серии:	JTO Clinical and Research Reports
Предметы:	RET Selpercatinib Non–small-cell lung carcinoma RET fusion NSCLC Case Report
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2666364324001000
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!